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A B S T R A C T   
Background: Human cytomegalovirus (HCMV) remains an important cause of transplant-related morbidity and 
mortality. The incidence of HCMV recurrence in the donor seronegative (D-)/recipient seropositive (R+) group is 
significantly higher than in other serostatus combinations as a result of a lack of pre-existing HCMV-specific 
memory T-lymphocytes in the donor, coupled with the eradication of the recipient’s cellular immunity due to the 
conditioning regimen. 
Case presentation: We describe the case of an 8-year-old βE-thalassemic girl from Bangladesh who was seropos-
itive for human cytomegalovirus (HCMV) and underwent hematopoietic stem cell transplantation from a HLA- 
matched, unrelated, HCMV-seronegative donor. Despite administering antiviral prophylaxis with commercial 
pooled anti-HCMV immunoglobulin (Ig) from day +1, the post-transplant course was complicated by prompt 
viral reactivation, and foscarnet therapy was initiated. The virus was refractory to treatment, leading rapidly to 
complete bone marrow failure, and targeted immunotherapy was proposed as a second-line therapy. Hypothe-
sizing that the patient and her relatives may have been exposed to similar HCMV strains, we selected the pa-
tient’s mother, who presented a high HCMV antibody titer, as the donor of virus strain-specific anti-HCMV Ig and 
T-lymphocytes. Complete viral clearance was achieved after two transfusions of the mother’s plasma. Subse-
quently, the patient underwent a haploidentical rescue transplant, promptly reaching full hematological 
recovery. 
Conclusion: These findings suggest that treatment with virus strain-specific Ig may offer a new therapeutic option 
for critically ill patients.   
1. Introduction 
Human cytomegalovirus (HCMV) is the most significant cause of 
opportunistic viral infection in allogeneic hematopoietic stem cell 
transplantation (HSCT) and remains an important cause of transplant- 
related morbidity and mortality (Wagner-Drouet et al., 2019). Several 
studies have shown that the incidence of HCMV recurrence in the donor 
seronegative (D-)/recipient seropositive (R+) group is significantly 
higher than in other serostatus combinations (Ganepola et al., 2007; 
Zhou et al., 2009; Ozdemir et al., 2007). This is likely a consequence of 
delayed HCMV-specific immune reconstitution due to the lack of 
pre-existing HCMV-specific memory T-lymphocytes in the donor, 
coupled with the eradication of the recipient’s cellular immunity due to 
the conditioning regimen (Styczynski, 2018; Ljungman et al., 2014). 
HCMV infection can lead to pneumonia, gastroenteritis, retinitis, hep-
atitis, and encephalitis among HSCT recipients (Griffiths, 2012). In 
addition, HCMV infection of the bone marrow can result in impaired 
graft acceptance and, in the most extreme cases, complete graft failure 
(Steffens et al., 1998). Treatment of HCMV disease essentially consists of 
administering antiviral drugs, namely ganciclovir and foscarnet, and 
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intravenous immunoglobulin. Although chemoprophylaxis is not 
generally recommended in HSCT, immunoglobulin, whether pooled or 
HCMV-specific, have shown some efficacy in preventing recurrent 
HCMV infections (Boeckh and Ljungman, 2009). 
We describe a case of a pediatric HSCT recipient who had compli-
cations of HCMV recurrence and was treated successfully with targeted 
immunological therapy, using haploidentical donor-derived immuno-
globulin (Ig). 
2. Case presentation 
An 8-year-old girl was diagnosed at the age of two in her country of 
origin (Bangladesh) as βE-thalassemic. She was treated with monthly 
blood transfusions and weekly iron chelation with deferoxamine, plus 
supplementation with folic acid. A suboptimal regimen of chelation 
therapy led to severe systemic siderosis, and her family travelled to Italy 
to undergo HSCT. Since a human leukocyte antigen (HLA)-matched 
related donor was unavailable at that time, an HLA-matched (10/10) 
unrelated donor was identified. The patient was HCMV-seropositive, 
whereas the donor was HCMV-seronegative, thus posing a high-risk 
serological combination (D-/R+) for post-transplant HCMV infection 
and associated complications. 
The conditioning regimen consisted of fludarabine, busulfan, thio-
tepa, and anti-thymocyte globulin (ATG). The infused donor’s bone 
marrow contained 3.79 × 108 total nuclear cells/kg recipient weight, 
and the vitality of the cells contained in the graft was 96.9%. Tacrolimus 
and mycophenolate mofetil were used for graft-versus-host disease 
(GVHD) prophylaxis. Anti-HCMV prophylaxis commenced at day +1 
with commercial pooled anti-HCMV Ig (Megalotect, Biotest Pharma 
GmbH, Germany) at a dose of 100 U/kg twice a week. 
The initial post-transplant period was uneventful. The first occur-
rence of HCMV viremia (600 viral genome copies/mL) was detected at 
day +14, and antiviral therapy with foscarnet was started immediately. 
At day +17, neutrophil engraftment was achieved, but not the platelet 
and the erythrocyte counterparts. At day +20, the patient presented 
fever without clinical symptoms and without an increase of C-reactive 
protein. Afterwards, a full blood count revealed a progressive drop in 
leukocytes and platelets, whereas HCMV viremia continued to increase 
despite antiviral therapy. The patient also developed a severe, HCMV- 
related hemorrhagic cystitis, which required frequent platelet trans-
fusions, initially once daily for 5 days, and thereafter twice daily for 7 
days. 
As the infection appeared unresponsive to foscarnet, ganciclovir 
treatment was started at day +25. This switch in antiviral therapy fol-
lowed an increase in viral load, reaching a maximum titer of 5100 viral 
genome copies/mL at day +30. Simultaneously, the clinical condition of 
the patient continued to deteriorate, and the leukocyte count decreased 
drastically. Therefore, the diagnosis of secondary graft failure due to 
HCMV infection was established. Because of the failure of anti-HCMV 
treatment, ganciclovir was withdrawn, and foscarnet therapy was 
resumed. The possible explanations for treatment failure include the 
presence of antiviral resistance mutations or an ineffective activity of the 
Ig administered. As the first option seemed improbable because resis-
tance mutations usually arise later than 6 weeks after HSCT, we opted to 
address the latter option. Therefore, we considered using antibodies 
(Abs) that were more likely to inhibit the HCMV strains causing the 
infection in the patient. Although the diversity of circulating HCMV 
strains is known to be extensive (Puchhammer-Stöckl and Görzer, 2011), 
we hypothesized that the patient and her relatives may have been 
exposed to similar strains on a familial basis. As a result, we performed 
serological tests on the patient’s mother, father and brother. We selected 
the patient’s mother, who presented the highest anti-HCMV IgG titer, as 
the best donor of strain-specific HCMV Ab-rich plasma and virus-specific 
T-lymphocytes in this situation. At day +32, the patient’s mother un-
derwent leukapheresis. The lymphocytes were sent immediately to a cell 
factory to produce specific anti-HCMV T-lymphocytes. On the same day, 
the plasma enriched in HCMV strain-specific Abs was infused into the 
patient. At day +34, the viral load decreased for the first time, to 1100 
viral genome copies/mL, and the patient began new conditioning for a 
haploidentical rescue transplant from her mother. In light of the con-
current bone marrow aplasia, the conditioning regimen was conducted 
solely with ATG. At day +38, the girl received a second plasma trans-
fusion from her mother. On the day of the second transplant (day +40), 
complete viral clearance was documented, and the girl received 11.3 ×
106 CD34 cells/kg of mother’s graft. GVHD prophylaxis was performed 
with post-transplant cyclophosphamide, tacrolimus, and mycophenolate 
mofetil. The engraftment was rapid, with a neutrophil count of >500/μL 
achieved at day +15, and the final platelets and packed red blood cells 
were transfused at day +20. Since HCMV viremia remained negative 
during the entire post-transplant period, we discarded the use of the 
mother’s virus-specific T-lymphocytes. The patient was discharged at 
day +27 in perfect clinical condition, with continuation of antiviral 
valganciclovir prophylaxis. Immunosuppressive treatment and antiviral 
prophylaxis were discontinued six months later, and the patient remains 
in perfect health 2 years after the second transplant. 
Therapeutic interventions, HCMV load, and white blood cell count 
during the entire episode are summarized in Fig. 1. In addition, the 
HCMV strains present in the patient were characterized by high- 
throughput sequencing (HTS) of an archived (− 80 ◦C) plasma sample 
from day +19. DNA was extracted from 800 μl of plasma using a 
QIAamp MinElute virus spin kit (QIAGEN, Crawley, UK). An aliquot of 
50 μl of DNA was used to generate an HCMV-enriched sequencing li-
brary as described previously (Suárez et al., 2019). The library was 
loaded onto a NextSeq DNA sequencer (Illumina, San Diego, CA, USA), 
generating 150 bp paired-ended reads (Table 1). HCMV strain 
enumeration was performed by genotyping 12 hypervariable HCMV 
genes from the reads as described previously (Suárez et al., 2019). The 
detection of four genotypes of the RL13 gene indicated the presence of at 
least four HCMV strains (a strain being defined as a particular constel-
lation of genotypes of the hypervariable genes analysed), each including 
one of these RL13 genotypes (Table 2). The data was also inspected for 
the presence of resistance mutations in the antiviral target genes (UL54 
and UL97) using LoFreq (Wilm et al., 2012). Briefly, the reads were 
mapped to the genome of HCMV reference strain Merlin (GenBank 
accession no. AY446894.2), and non-synonymous variants known to 
confer resistance were identified. No resistance mutations were 
detected. 
3. Discussion 
Various factors are implicated in the outcome of HCMV infection in 
transplant patients, the first of which relates to the HCMV serological 
status of donor and recipient. The serological status of the first donor 
may have played an important role in this case, as it has been reported 
that using an HCMV-seronegative unrelated HSCT donor (D-) for a 
seropositive recipient (R+) results in reduced overall survival after 
myeloablative conditioning. In contrast, an HCMV seropositive donor is 
associated with improved event-free survival and reduced non-relapse 
mortality (Styczynski, 2018). Thus, the absence of an HCMV-specific 
immunological memory in the donor’s cells may have placed the 
HCMV-positive recipient at a higher risk of HCMV reactivation and 
associated complications. 
In relation to viral factors, the clinical course of the patient may have 
been influenced by two main factors: the presence of multiple HCMV 
strains or the presence of mutations conferring antiviral resistance. 
Infection with multiple HCMV strains is common after transplantation 
(Görzer et al., 2010), and is associated with delayed HCMV clearance 
during antiviral therapy, even in the absence of antiviral resistance 
mutations. It is also associated with worse clinical outcomes, including 
an increase in graft rejection and faster progression of disease. In prin-
ciple, the mechanisms behind this increased pathogenicity can be viral, 
for example involving recombination and complementation of different 
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strains within the host, or immunological, since control of multiple 
strains may be more challenging for the immune system. Overall, in 
clinically symptomatic immunocompromised hosts, the presence of 
multiple HCMV strains is more threatening than the presence of a single 
strain (Manuel et al., 2009). 
In the present study, the initial failure of antiviral therapy could not 
be explained by the development of resistance mutations in the HCMV 
strains present in the patient. This finding is not surprising, as detection 
of resistance mutations is unusual during the first 6 weeks of antiviral 
therapy, whereas the sample analysed in this case was collected only 13 
days after initiation of foscarnet treatment (Lurain and Chou, 2010; 
Springer et al., 2005). 
In regard to the initial failure of the immunotherapy with commer-
cial pooled Ig, this may have been due to the lack of particular Abs with 
neutralizing capacity against the HCMV strains present in the patient. 
Assuming that the donors providing the Ig had been exposed to strains 
circulating in Europe, the Abs may have been more suited for 
Fig. 1. Information on viremia, white blood cell (WBC) count, total serum IgG and antiviral therapy. Data on HCMV viremia is expressed in viral genome copies/mL 
(right Y-axis). Application and duration of antiviral treatments are represented by colored bars (yellow, anti-HCMV-specific Ig; red, foscarnet; blue, ganciclovir/ 
valganciclovir). Chronological data (X-axis) are represented in days after the first transplant. The plasma sample analysed by high-throughput sequencing (HTS) is 
represented by a filled blue circle. 
Table 1 
Overview of HTS data.  
Sample ID TRI-SCT1 
Sample type Plasma 
Days after transplant +19 
HCMV load (genome copies/mL) 2100 
Data deposition (ENA project no.)a PRJEB38333 
Sequencing library (genome copies) 1440 
Trimmed reads (no.) 5,033,480 
HCMV reads (no.)b 936,773 
HCMV reads; %b 19 
Coverage depth (reads/nt)b 885  
a The sequence dataset was purged of human reads and deposited in the 
European Nucleotide Archive (ENA). 
b Reads mapped to the HCMV reference strain Merlin genome; HTS, 
high-throughput sequencing; nt, nucleotide. 
Table 2 
Genotyping of hypervariable HCMV genes. 
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neutralizing HCMV strains commonly circulating in that region. How-
ever, it is possible that the strains present in the patient, who originated 
from Bangladesh, may have differed immunologically from strains in 
other regions of the world. The extent to which this is true is unknown, 
as current knowledge of HCMV genome variability is derived almost 
entirely from strains circulating in a few European countries. Therefore, 
it would be useful to assess the neutralizing capacity of commercial 
pooled Ig in order to avoid potential therapeutic failure, especially in 
patients from non-European countries. The clinical problem in this case 
was addressed successfully by using the Ab-rich plasma of the patient’s 
mother in a kind of personalized immunotherapy, on the premise that 
both mother and daughter may have been exposed to the same pool of 
viral strains. In this HCMV-positive recipient with a severe viral reac-
tivation, Ig obtained from a household donor afforded an efficacious 
treatment that led to complete viral clearance. 
To the best of our knowledge, this is the first report of the successful 
use of HCMV strain-specific Ig therapy in an HSCT recipient. The effi-
cacy of this approach as a means of prevention has been demonstrated 
previously only in mouse models involving murine cytomegalovirus 
(MCMV) reactivation after bone marrow transplantation (Martins et al., 
2019). In this setting, mice received serum obtained either from latently 
infected (seropositive) donors or from seronegative donors. The transfer 
of immune serum protected mice from viral reactivation without 
affecting the development of GVHD. Remarkably, complete viral pro-
tection was obtained with a small volume (5 μL) of strain-specific im-
mune serum. On the other hand, when specific donor antibodies were 
administered to mice infected with antigenically mismatched MCMV 
strains, they were not efficient in preventing viral reactivation. 
Our case highlights the importance of monitoring HSCT recipients 
comprehensively, longitudinally and with high sensitivity for viral fac-
tors, including the presence of multiple strains and resistance mutations. 
Importantly, it also provides an affordable targeted immunological 
therapy in patients from countries with constrained access to alternative 
therapies. 
4. Conclusion 
HSCT is a complex and specific setting in which a recipient may 
rapidly develop viral reactivation and consequent life-threatening 
complications. Ab-rich plasma may represent a fast and feasible thera-
peutic option to overcome viral activity and allow successful engraft-
ment of the donor’s bone marrow. 
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